|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Li DQ, Nair SS and Kumar R: The MORC
family: New epigenetic regulators of transcription and DNA damage
response. Epigenetics. 8:685–693. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang GL, Wang CY, Cai XZ, Chen W, Wang XH
and Li F: Identification and expression analysis of a novel CW-type
zinc finger protein MORC2 in cancer cells. Anat Rec (Hoboken).
293:1002–1009. 2010. View
Article : Google Scholar
|
|
4
|
Moissiard G, Cokus SJ, Cary J, Feng S,
Billi AC, Stroud H, Husmann D, Zhan Y, Lajoie BR, McCord RP, et al:
MORC family ATPases required for heterochromatin condensation and
gene silencing. Science. 336:1448–1451. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shao Y, Li Y, Zhang J, Liu D, Liu F, Zhao
Y, Shen T and Li F: Involvement of histone deacetylation in
MORC2-mediated down-regulation of carbonic anhydrase IX. Nucleic
Acids Res. 38:2813–2824. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li DQ, Nair SS, Ohshiro K, Kumar A, Nair
VS, Pakala SB, Reddy SD, Gajula RP, Eswaran J, Aravind L, et al:
MORC2 signaling integrates phosphorylation-dependent,
ATPase-coupled chromatin remodeling during the DNA damage response.
Cell Rep. 2:1657–1669. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sánchez-Solana B, Li DQ and Kumar R:
Cytosolic functions of MORC2 in lipogenesis and adipogenesis.
Biochimica et Biophysica Acta (BBA). Mol Cell Res. 1843:316–326.
2014.
|
|
8
|
Chen LH, Kuo W-H, Tsai M-H, Chen P-C,
Hsiao CK, Chuang EY, Chang LY, Hsieh FJ, Lai LC and Chang KJ:
Identification of prognostic genes for recurrent risk prediction in
triple negative breast cancer patients in Taiwan. PLoS One.
6:e282222011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liao XH, Zhang Y, Dong WJ, Shao ZM and Li
DQ: Chromatin remodeling protein MORC2 promotes breast cancer
invasion and metastasis through a PRD domain-mediated interaction
with CTNND1. Oncotarget. 8:97941–97954. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tong Y, Li Y, Gu H, Wang C, Liu F, Shao Y
and Li F: HSF1, in association with MORC2, downregulates ArgBP2 via
the RC2 family in gastric cancer cells. Biochim Biophys Acta.
1864:1104–1114. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang G, Song Y, Liu T, Wang C, Zhang Q,
Liu F, Cai X, Miao Z, Xu H, Xu H, et al: PAK1-mediated MORC2
phosphorylation promotes gastric tumorigenesis. Oncotarget.
6:9877–9886. 2015.PubMed/NCBI
|
|
12
|
Zhang Q, Song Y, Chen W, Wang X, Miao Z,
Cao L, Li F and Wang G: By recruiting HDAC1, MORC2 suppresses p21
Waf1/Cip1 in gastric cancer. Oncotarget. 6:16461–16470.
2015.PubMed/NCBI
|
|
13
|
Roessler S, Jia HL, Budhu A, Forgues M, Ye
QH, Lee JS, Thorgeirsson SS, Sun Z, Tang ZY, Qin LX, et al: A
unique metastasis gene signature enables prediction of tumor
relapse in early-stage hepatocellular carcinoma patients. Cancer
Res. 70:10202–10212. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Burchard J, Zhang C, Liu AM, Poon RT, Lee
NP, Wong KF, Sham PC, Lam BY, Ferguson MD, Tokiwa G, et al:
microRNA-122 as a regulator of mitochondrial metabolic gene network
in hepatocellular carcinoma. Mol Syst Biol. 6:4022010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu AM, Yao TJ, Wang W, Wong KF, Lee NP,
Fan ST, Poon RT, Gao C and Luk JM: Circulating miR-15b and miR-130b
in serum as potential markers for detecting hepatocellular
carcinoma: A retrospective cohort study. BMJ Open. 2:e0008252012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBio-Portal. Sci Signal. 6:pl12013. View Article : Google Scholar
|
|
17
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: an open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
19
|
Ding Q, He K, Luo T, Deng Y, Wang H, Liu
H, Zhang J, Chen K, Xiao J, Duan X, et al: SSRP1 Contributes to the
Malignancy of Hepatocellular Carcinoma and Is Negatively Regulated
by miR-497. Mol Ther. 24:903–914. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tao ZH, Wan JL, Zeng LY, Xie L, Sun HC,
Qin LX, Wang L, Zhou J, Ren ZG, Li YX, et al: miR-612 suppresses
the invasive-metastatic cascade in hepatocellular carcinoma. J Exp
Med. 210:789–803. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li P, Lin Y, Zhang Y, Zhu Z and Huo K:
SSX2IP promotes metastasis and chemotherapeutic resistance of
hepatocellular carcinoma. J Transl Med. 11:522013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Arakawa H: p53, apoptosis and
axon-guidance molecules. Cell Death Differ. 12:1057–1065. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wu B, Chu X, Feng C, Hou J, Fan H, Liu N,
Li C, Kong X, Ye X and Meng S: Heat shock protein gp96 decreases
p53 stability by regulating Mdm2 E3 ligase activity in liver
cancer. Cancer Lett. 359:325–334. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cui X, Choi HK, Choi YS, Park SY, Sung GJ,
Lee YH, Lee J, Jun WJ, Kim K, Choi KC, et al: DNAJB1 destabilizes
PDCD5 to suppress p53-mediated apoptosis. Cancer Lett. 357:307–315.
2015. View Article : Google Scholar
|
|
26
|
Kumar Y, Yang J, Hu T, Chen L, Xu Z, Xu L,
Hu XX, Tang G, Wang JM, Li Y, et al: Massive interstitial
copy-neutral loss-of-heterozygosity as evidence for cancer being a
disease of the DNA-damage response. BMC Med Genomics. 8:422015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Stuhldreier F, Kassel S, Schumacher L,
Wesselborg S, Proksch P and Fritz G: Pleiotropic effects of
spongean alkaloids on mechanisms of cell death, cell cycle
progression and DNA damage response (DDR) of acute myeloid leukemia
(AML) cells. Cancer Lett. 361:39–48. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ho H, Aruri J, Kapadia R, Mehr H, White MA
and Ganesan AK: RhoJ regulates melanoma chemoresistance by
suppressing pathways that sense DNA damage. Cancer Res.
72:5516–5528. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jia H, Cong Q, Chua JF, Liu H, Xia X,
Zhang X, Lin J, Habib SL, Ao J, Zuo Q, et al: p57Kip2 is an
unrecognized DNA damage response effector molecule that functions
in tumor suppression and chemoresistance. Oncogene. 34:3568–3581.
2015. View Article : Google Scholar
|
|
30
|
Wang L, Mosel AJ, Oakley GG and Peng A:
Deficient DNA damage signaling leads to chemoresistance to
cisplatin in oral cancer. Mol Cancer Ther. 11:2401–2409. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yang SF, Chang CW, Wei RJ, Shiue YL, Wang
SN and Yeh YT: Involvement of DNA damage response pathways in
hepatocellular carcinoma. Biomed Res Int.
2014:1538672014.PubMed/NCBI
|
|
32
|
Hong L, Cai Y, Jiang M, Zhou D and Chen L:
The Hippo signaling pathway in liver regeneration and
tumorigenesis. Acta Biochim Biophys Sin (Shanghai). 47:46–52. 2015.
View Article : Google Scholar
|
|
33
|
Zheng T, Wang J, Jiang H and Liu L: Hippo
signaling in oval cells and hepatocarcinogenesis. Cancer Lett.
302:91–99. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hong W and Guan KL: The YAP and TAZ
transcription co-activators: Key downstream effectors of the
mammalian Hippo pathway. Semin Cell Dev Biol. 23:785–793. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Aragona M, Panciera T, Manfrin A, Giulitti
S, Michielin F, Elvassore N, Dupont S and Piccolo S: A mechanical
checkpoint controls multicellular growth through YAP/TAZ regulation
by actin-processing factors. Cell. 154:1047–1059. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bae JS, Kim SM and Lee H: The Hippo
signaling pathway provides novel anti-cancer drug targets.
Oncotarget. 8:16084–16098. 2017. View Article : Google Scholar :
|
|
37
|
Zanconato F, Cordenonsi M and Piccolo S:
YAP/TAZ at the roots of cancer. Cancer Cell. 29:783–803. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Anekal PV, Yong J and Manser E: Arg
kinase-binding protein 2 (ArgBP2) interaction with α-actinin and
actin stress fibers inhibits cell migration. J Biol Chem.
290:2112–2125. 2015. View Article : Google Scholar
|
|
39
|
Cestra G, Toomre D, Chang S and De Camilli
P: The Abl/Arg substrate ArgBP2/nArgBP2 coordinates the function of
multiple regulatory mechanisms converging on the actin
cytoskeleton. Proc Natl Acad Sci USA. 102:1731–1736. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Tong Y, Li Y, Gu H, Wang C, Liu F, Shao Y,
Li J, Cao L and Li F: Microchidia protein 2, MORC2, downregulates
the cytoskeleton adapter protein, ArgBP2, via histone methylation
in gastric cancer cells. Biochem Biophys Res Commun. 467:821–827.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ni F, Zhao H, Cui H, Wu Z, Chen L, Hu Z,
Guo C, Liu Y, Chen Z, Wang X, et al: MicroRNA-362-5p promotes tumor
growth and metastasis by targeting CYLD in hepatocellular
carcinoma. Cancer Lett. 356:809–818. 2015. View Article : Google Scholar
|
|
42
|
Liu J, Han P, Li M, Yan W, Liu J, Liu J,
He J, Tu W, Xia Y, Zhou Z, et al: The histidine-rich calcium
binding protein (HRC) promotes tumor metastasis in hepatocellular
carcinoma and is upregulated by SATB1. Oncotarget. 6:6811–6824.
2015.PubMed/NCBI
|
|
43
|
Calvisi DF, Wang C, Ho C, Ladu S, Lee SA,
Mattu S, Destefanis G, Delogu S, Zimmermann A, Ericsson J, et al:
Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling,
promotes development of human hepatocellular carcinoma.
Gastroenterology. 140:1071–1083. 2011. View Article : Google Scholar :
|
|
44
|
Wang C, Rajput S, Watabe K, Liao DF and
Cao D: Acetyl-CoA carboxylase-a as a novel target for cancer
therapy. Front Biosci (Schol Ed). 2:515–526. 2010.
|
|
45
|
Wang Y and He D, Yang L, Wen B, Dai J,
Zhang Q, Kang J, He W, Ding Q and He D: TRIM26 functions as a novel
tumor suppressor of hepatocellular carcinoma and its downregulation
contributes to worse prognosis. Biochem Biophys Res Commun.
463:458–465. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Laššuthová P, Šafka Brožková D, Krůtová M,
Mazanec R, Züchner S, Gonzalez MA and Seeman P: Severe axonal
Charcot-Marie-Tooth disease with proximal weakness caused by de
novo mutation in the MORC2 gene. Brain. 139:e262016. View Article : Google Scholar
|
|
47
|
Zhao X, Li X, Hu Z, Liu L, Xie Y, Tian T,
Man J, Wang J, Zi X, Xia K, et al: MORC2 mutations in a cohort of
Chinese patients with Charcot-Marie-Tooth disease type 2. Brain.
139:e562016. View Article : Google Scholar : PubMed/NCBI
|
